Rocatinlimab prefilled syringe

COMBINATION_PRODUCT2 trials

Sponsors

Amgen

Conditions

Atopic Dermatitis

Phase 1

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

CompletedNCT06268860

AmgenAtopic Dermatitis

Start: 2024-02-15End: 2024-10-08Updated: 2025-12-23

Phase 3

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

CompletedNCT06224192

AmgenAtopic Dermatitis

Start: 2024-04-02End: 2026-03-16Updated: 2026-03-25

Related Papers

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis

Immunotherapy2025-01-228 citations